Skip to main content

Table 2 Summary of phenotypes in whole-lung cells of bleomycin (BLM)- or BLM + pirfenidone-treated mice determined through fluorescence-activated cell sorter analysis in a therapeutic setting *

From: Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis

  Percentage of cells
Treatment CD45-/Col-I- CD45+/Col-I- CD45-/Col-I+ CD45+/Col-I + (Fibrocyte)
Saline 64.8 ± 9.5 9.76 ± 13.6 15.3 ± 21.4 10.1 ± 1.7
BLM 25.1 ± 3.0 16.1 ± 22.0 33.1 ± 25.0 25.6 ± 5.9
BLM + pirfenidone 47.8 ± 7.2 6.8 ± 8.7 27.8 ± 7.8 17.6 ± 6.4
  1. *Data are shown as the percentage of cells that are positive (+) or negative (−) for CD45 or collagen I (Col-I) in whole-lung cells. Data shown represent the means ± standard error from 6 saline-, BLM- or BLM + pirfenidone-treated mice, respectively, and are representative of 2 independent experiments.